Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO – Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society)
This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society SOLAPSO, who assessed the quality of the available evidence using the GRADE system and the PICO process to guide the literat...
Saved in:
| Published in: | International journal of dermatology Vol. 58; no. S1; pp. 4 - 28 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Blackwell Publishing Ltd
01-08-2019
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society SOLAPSO, who assessed the quality of the available evidence using the GRADE system and the PICO process to guide the literature search. To answer each question, the experts discussed the results of randomized controlled trials, observational studies and metanalysis evaluating the interventions identified (non‐biologics, biologics and phototherapy) in different populations of patients with moderate to severe plaque‐psoriasis, which was summarized in Tables ad‐hoc. The main end‐points considered to assess efficacy were PASI 50, 75, 90 and 100, PGA 0‐1 and significant improvement of health‐related quality of life. Specific adverse events, either severe or leading to treatment interruption, were also evaluated. The 31 recommendations included in this CPG follow the structure proposed by GRADE: direction (for or against) and strength (strong or weak). The goal of this CPG is to improve the management of patients with psoriasis by recommending interventions of proved benefit and providing a reference standard for the treating physician. Adhering to the contents of this CPG does not guarantee therapeutic success. The final decision on the specific treatment is the responsibility of the physician based on the individual circumstances and considering the values, the preferences and the opinions of the patient or caregivers. |
|---|---|
| AbstractList | This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society
SOLAPSO
, who assessed the quality of the available evidence using the
GRADE
system and the
PICO
process to guide the literature search. To answer each question, the experts discussed the results of randomized controlled trials, observational studies and metanalysis evaluating the interventions identified (non‐biologics, biologics and phototherapy) in different populations of patients with moderate to severe plaque‐psoriasis, which was summarized in Tables ad‐hoc. The main end‐points considered to assess efficacy were
PASI
50, 75, 90 and 100,
PGA
0‐1 and significant improvement of health‐related quality of life. Specific adverse events, either severe or leading to treatment interruption, were also evaluated. The 31 recommendations included in this
CPG
follow the structure proposed by
GRADE
: direction (for or against) and strength (strong or weak). The goal of this
CPG
is to improve the management of patients with psoriasis by recommending interventions of proved benefit and providing a reference standard for the treating physician. Adhering to the contents of this
CPG
does not guarantee therapeutic success. The final decision on the specific treatment is the responsibility of the physician based on the individual circumstances and considering the values, the preferences and the opinions of the patient or caregivers. This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society SOLAPSO, who assessed the quality of the available evidence using the GRADE system and the PICO process to guide the literature search. To answer each question, the experts discussed the results of randomized controlled trials, observational studies and metanalysis evaluating the interventions identified (non-biologics, biologics and phototherapy) in different populations of patients with moderate to severe plaque-psoriasis, which was summarized in Tables ad-hoc. The main end-points considered to assess efficacy were PASI 50, 75, 90 and 100, PGA 0-1 and significant improvement of health-related quality of life. Specific adverse events, either severe or leading to treatment interruption, were also evaluated. The 31 recommendations included in this CPG follow the structure proposed by GRADE: direction (for or against) and strength (strong or weak). The goal of this CPG is to improve the management of patients with psoriasis by recommending interventions of proved benefit and providing a reference standard for the treating physician. Adhering to the contents of this CPG does not guarantee therapeutic success. The final decision on the specific treatment is the responsibility of the physician based on the individual circumstances and considering the values, the preferences and the opinions of the patient or caregivers. |
| Author | Valenzuela, Fernando Barahona‐Torres, Lilia Castro Vargas, Evelyn G. Raimondo, Nélida Diez de Medina, Juan C. Kogan, Nora Quintana, Gerardo B. Franco, Manuel Gusis, Simon E. Martínez López, Jaime E. Abarca Duran, Jorge A. Criniti, Juan Izcovich, Ariel Blanco, Orestes Gómez, Minerva Levrero, Verónica P. Castro, Carla Briones, María C. |
| Author_xml | – sequence: 1 givenname: Nora surname: Kogan fullname: Kogan, Nora email: nnkogan@yahoo.com.ar organization: Hospital Ramos Mejía – sequence: 2 givenname: Nélida surname: Raimondo fullname: Raimondo, Nélida organization: Hospital Aeronáutico Central – sequence: 3 givenname: Simon E. surname: Gusis fullname: Gusis, Simon E. organization: Hospital Ramos Mejía – sequence: 4 givenname: Ariel surname: Izcovich fullname: Izcovich, Ariel organization: Hospital Aleman – sequence: 5 givenname: Jorge A. surname: Abarca Duran fullname: Abarca Duran, Jorge A. organization: Hospital CIMA San José – sequence: 6 givenname: Lilia surname: Barahona‐Torres fullname: Barahona‐Torres, Lilia organization: Instituto Hondureño de Seguridad Social – sequence: 7 givenname: Orestes surname: Blanco fullname: Blanco, Orestes organization: Institute of Tropical Medicine Pedro Kouri – sequence: 8 givenname: Gerardo B. surname: Quintana fullname: Quintana, Gerardo B. organization: Centro Clínico Cutáneo – sequence: 9 givenname: María C. surname: Briones fullname: Briones, María C. organization: Centro Privado de Piel “Dr. Enrique Uraga” – sequence: 10 givenname: Carla surname: Castro fullname: Castro, Carla organization: Hospital Universitario Austral – sequence: 11 givenname: Evelyn G. surname: Castro Vargas fullname: Castro Vargas, Evelyn G. organization: Clínica San Felipe – sequence: 12 givenname: Juan surname: Criniti fullname: Criniti, Juan organization: Hospital Aleman – sequence: 13 givenname: Juan C. surname: Diez de Medina fullname: Diez de Medina, Juan C. organization: Fundación Piel Bolivia – sequence: 14 givenname: Manuel surname: Franco fullname: Franco, Manuel organization: Universidad del Bosque – sequence: 15 givenname: Minerva surname: Gómez fullname: Gómez, Minerva organization: University Hospital – sequence: 16 givenname: Verónica P. surname: Levrero fullname: Levrero, Verónica P. organization: Centro Dermatológico – sequence: 17 givenname: Jaime E. surname: Martínez López fullname: Martínez López, Jaime E. organization: Medicentro La Esperanza – sequence: 18 givenname: Fernando surname: Valenzuela fullname: Valenzuela, Fernando organization: Hospital Clinico Universidad de Chile |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31282026$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc9qGzEQxkVISRw3h7xAEeSSHDbWn11ZezROm6YYbHB6XmRplsrsSom0S_At79CH6Hv1SSrHbjGGzkUz4jffN_BdoFPnHSB0RckdTTWya3NH83xMT9CAclFkueDsFA0IoTQrSVGeo4sY12nkjOZn6JxTJhlhYoB-zVRnHZ60EKxWDk8b61LT4EVQurMa8ENvDaRfiNg73P0AvNzEDlqr8VMA1bXgOuxrvIg-WBVtxMv5bLJYzvHvt5946bUFowx-9_Fq76OwgYONm6MrDrS2-93m9iP6UKsmwuX-HaLvXz4_Tb9ms_nD43QyyzQvOM1WNHkJJnk9VpyOCdGiKPNc0FqvcqO0oACga5JLo6koJKlNoYlUNSulIkzzIbrZ6T4H_9JD7KrWRg1Noxz4PlaMFVwySQRP6PURuvZ9cOm6LcXKYixJmajbHaWDjzFAXT0H26qwqSiptulVKb3qPb3Eftor9qsWzD_yb1wJGO2AV9vA5v9K1eO3-53kH_TZp0Q |
| CitedBy_id | crossref_primary_10_1111_dth_13243 crossref_primary_10_1111_bjd_21047 crossref_primary_10_1016_j_ad_2021_09_007 crossref_primary_10_1093_bjd_ljac128 crossref_primary_10_1007_s11096_020_01061_w crossref_primary_10_25208_vdv1109 crossref_primary_10_1080_09546634_2021_1914306 crossref_primary_10_25208_0042_4609_2019_95_4_87_93 crossref_primary_10_1016_j_ad_2023_09_001 crossref_primary_10_1016_j_ad_2021_09_004 crossref_primary_10_1016_j_ad_2023_02_002 crossref_primary_10_1097_MD_0000000000021913 crossref_primary_10_1097_MD_0000000000022539 |
| Cites_doi | 10.1056/NEJMoa0810652 10.1111/jdv.12553 10.1111/j.1365-2230.2009.03693.x 10.1111/j.1365-2133.2007.08315.x 10.1111/j.1365-2133.2011.10418.x 10.1016/j.jaad.2006.09.002 10.1111/jdv.12749 10.1016/j.jaad.2015.07.002 10.2340/00015555-1845 10.1111/bjd.12214 10.1111/jdv.12343 10.1046/j.1523-1747.2003.12040.x 10.1136/ard.2008.092767 10.3109/09546634.2012.672710 10.1159/000357030 10.1111/j.1468-3083.2011.04394.x 10.1111/bjd.12150 10.1007/s40273-014-0226-y 10.1111/bjd.12112 10.1016/j.jdermsci.2010.04.014 10.1111/jdv.12751 10.1111/jdv.12004 10.3109/09546634.2013.848258 10.1155/2013/347520 10.1111/j.1468-3083.2012.04644.x 10.1056/NEJM199101313240501 10.1016/j.jclinepi.2012.08.001 10.1111/j.1365-2133.2011.10419.x 10.1016/j.jaad.2010.05.014 10.1016/S0140-6736(15)61134-5 10.1080/09546630500472838 10.1056/NEJMoa1314258 10.1136/annrheumdis-2013-203696 10.1111/jdv.12585 10.1093/rheumatology/kes001 10.1517/14712598.2012.646986 10.1007/s13555-016-0117-6 10.1016/j.jaad.2006.05.027 10.1016/j.jaad.2011.07.039 10.1016/S0140-6736(13)60594-2 10.1111/j.1365-2133.2005.06948.x 10.1111/j.1468-3083.2010.03927.x 10.1111/ijd.12511 10.1136/ard.2010.130864 10.1001/archderm.143.6.719 10.1016/j.ad.2015.01.010 10.1016/S0140-6736(17)31189-3 10.1111/j.1346-8138.2009.00748.x 10.1136/annrheumdis-2013-205056 10.1136/annrheumdis-2013-204902 10.2340/0001555577137141 10.1001/archderm.1995.01690190043008 10.1111/j.1365-2133.1988.tb03499.x 10.1136/ard.2005.035287 10.1016/j.jaad.2004.02.021 10.1093/rheumatology/keh562 10.1016/j.jaad.2011.07.034 10.1001/archdermatol.2011.2768 10.1001/archderm.142.8.1000 10.1067/mjd.2003.307 10.1111/pde.12940 10.1159/000320961 10.1111/j.1365-2133.2011.10615.x 10.1016/j.jaad.2006.07.017 10.1111/pde.12351 10.1056/NEJMoa030409 10.1111/j.1346-8138.2011.01347.x 10.1517/14740338.2014.959489 10.1016/j.jaad.2010.04.004 10.1002/art.34627 10.1016/S0140-6736(08)60726-6 10.1016/j.jaad.2006.02.010 10.1111/jdv.12011 10.1016/j.jdermsci.2011.05.005 10.1684/ejd.2011.1499 10.1007/s00403-015-1593-8 10.1111/j.1468-3083.2009.03389.x 10.1002/art.22379 10.1016/j.jaad.2004.10.766 10.2165/11530640-000000000-00000 10.1111/bjd.13060 10.1111/j.1346-8138.2007.00306.x 10.1111/j.1365-2133.2005.06688.x 10.1001/jamadermatol.2015.0718 10.1136/bmj.39489.470347.AD 10.1111/j.1525-1470.2008.00629.x 10.1016/j.jaad.2014.10.013 10.1016/j.ad.2011.12.018 10.1016/S0190-9622(88)70086-9 10.1016/S0140-6736(05)67566-6 10.1002/art.20335 10.1136/annrheumdis-2013-204655 10.1111/1346-8138.12668 10.1111/j.1365-2133.2010.09897.x 10.1111/j.1468-3083.2011.03984.x 10.1002/art.34436 10.1002/art.20967 10.1111/bjd.12110 10.1016/S0140-6736(00)02530-7 10.1111/j.1365-2133.2008.08727.x 10.1111/j.1365-2133.2007.08236.x 10.1111/j.1365-2133.2006.07237.x 10.1016/j.jaad.2007.09.010 10.1016/j.jaad.2010.09.734 10.3899/jrheum.140647 10.1111/j.1365-2230.2008.02907.x 10.1111/1346-8138.13306 10.1016/j.cgh.2009.11.023 10.1111/jdv.12359 10.1111/bjd.12404 10.1111/bjd.12941 10.1016/S0140-6736(00)04954-0 10.1016/j.reuma.2010.02.001 10.1001/archdermatol.2010.384 10.3899/jrheum.091093 10.1016/j.jaad.2015.05.013 10.1016/S0140-6736(05)67763-X 10.1111/j.1365-2133.2005.06510.x 10.1056/NEJMoa066886 10.1007/s10067-009-1340-7 10.1016/j.semarthrit.2015.05.003 10.1177/039463201002300418 10.1001/archderm.139.12.1627 10.1056/NEJMoa1412679 10.1111/j.1346-8138.2011.01312.x 10.1136/ard.2007.072967 10.1016/S0140-6736(09)60140-9 10.1111/j.1365-2133.2010.10139.x 10.1016/0190-9622(92)70072-N 10.1111/bjd.13348 10.1007/s10875-008-9233-0 10.1016/j.ad.2010.09.001 10.1016/j.jclinepi.2012.01.012 10.1016/S0140-6736(08)60725-4 |
| ContentType | Journal Article |
| Copyright | 2019 2019 The International Society of Dermatology. International Journal of Dermatology © 2019 International Society of Dermatology |
| Copyright_xml | – notice: 2019 – notice: 2019 The International Society of Dermatology. – notice: International Journal of Dermatology © 2019 International Society of Dermatology |
| DBID | NPM AAYXX CITATION 7T5 7U7 C1K H94 7X8 |
| DOI | 10.1111/ijd.14471 |
| DatabaseName | PubMed CrossRef Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed AIDS and Cancer Research Abstracts |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-4632 |
| EndPage | 28 |
| ExternalDocumentID | 10_1111_ijd_14471 31282026 IJD14471 |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29J 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT NPM AAMNL AAYXX CITATION 7T5 7U7 C1K H94 7X8 |
| ID | FETCH-LOGICAL-c3531-b1dad6283f7a31700c6594461fcb4dac61eeecf048dc16580fd5c08af298a02c3 |
| IEDL.DBID | 33P |
| ISSN | 0011-9059 |
| IngestDate | Sat Aug 17 00:37:14 EDT 2024 Thu Oct 10 22:09:30 EDT 2024 Thu Nov 21 23:18:10 EST 2024 Sat Sep 28 08:37:42 EDT 2024 Sat Aug 24 01:11:50 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | S1 |
| Language | English |
| License | 2019 The International Society of Dermatology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3531-b1dad6283f7a31700c6594461fcb4dac61eeecf048dc16580fd5c08af298a02c3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Instructional Material/Guideline-3 ObjectType-Feature-4 content type line 23 ObjectType-Review-1 |
| PMID | 31282026 |
| PQID | 2252957809 |
| PQPubID | 5776 |
| PageCount | 25 |
| ParticipantIDs | proquest_miscellaneous_2253828063 proquest_journals_2252957809 crossref_primary_10_1111_ijd_14471 pubmed_primary_31282026 wiley_primary_10_1111_ijd_14471_IJD14471 |
| PublicationCentury | 2000 |
| PublicationDate | August 2019 2019-Aug 2019-08-00 20190801 |
| PublicationDateYYYYMMDD | 2019-08-01 |
| PublicationDate_xml | – month: 08 year: 2019 text: August 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Hoboken |
| PublicationTitle | International journal of dermatology |
| PublicationTitleAlternate | Int J Dermatol |
| PublicationYear | 2019 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | 2010; 16 2013; 66 2013; 65 2015; 73 2015; 72 2015; 386 2010; 101 2017; 390 2010; 221 2014; 25 2015; 307 2014; 371 2014; 28 1995; 131 2012; 125 2012; 12 2014; 23 2016; 33 2010; 23 2013; 2013 2010; 29 2011; 70 2015; 373 2008; 25 2016; 43 2011; 64 2011; 63 2003; 48 2011; 65 2014; 13 2008; 358 2010; 8 2009; 68 2010; 37 2011; 2 2010; 35 1988; 18 2000; 356 2006; 55 2008; 58 2010; 163 2012; 39 2014; 41 2012; 103 2011; 7 2016; 6 2011; 147 2004; 50 2003; 349 2004; 51 2005; 366 1992; 26 1991; 324 2008; 371 2014; 31 2012; 163 2010; 59 2013; 27 2013; 24 2007; 143 2015; 33 2013; 168 2011; 12 2015; 106 2014; 171 2007; 34 2010; 63 2012; 51 2015; 45 2015; 172 2006; 65 2013; 12 2015; 42 2008; 67 2011; 21 2008; 159 2008; 158 2011; 25 2012; 67 2007; 25 2012; 64 2003; 120 2006; 367 2011; 165 2014; 53 2011; 164 2009; 23 2015; 14 2003; 139 2005; 152 2005; 153 2012 2015; 95 1995; 13 2006; 17 2006; 154 2010; 362 2013; 382 2006; 1 2011; 36 2009; 373 2012; 148 2007; 56 2005; 44 2009; 29 2015; 151 2009; 34 2014; 228 2015; 29 1997; 77 2005; 52 2006; 142 2008; 336 2014; 73 1988; 119 2001; 357 e_1_2_12_6_1 e_1_2_12_130_1 e_1_2_12_17_1 e_1_2_12_157_1 e_1_2_12_115_1 e_1_2_12_153_1 e_1_2_12_134_1 e_1_2_12_108_1 e_1_2_12_20_1 e_1_2_12_66_1 Sociedad Latinoamericana de Psoriasis (e_1_2_12_2_1) 2010; 16 Zhu X (e_1_2_12_62_1) 2013; 12 e_1_2_12_43_1 e_1_2_12_85_1 e_1_2_12_24_1 e_1_2_12_47_1 e_1_2_12_89_1 Cutolo M (e_1_2_12_138_1) 2013; 65 Richetta AG (e_1_2_12_111_1) 2012; 163 e_1_2_12_81_1 e_1_2_12_161_1 e_1_2_12_100_1 e_1_2_12_123_1 e_1_2_12_146_1 e_1_2_12_104_1 e_1_2_12_127_1 e_1_2_12_142_1 e_1_2_12_31_1 e_1_2_12_77_1 e_1_2_12_54_1 e_1_2_12_96_1 e_1_2_12_139_1 e_1_2_12_35_1 e_1_2_12_58_1 e_1_2_12_12_1 e_1_2_12_73_1 Bogas M (e_1_2_12_76_1) 2011; 36 e_1_2_12_92_1 e_1_2_12_3_1 e_1_2_12_152_1 e_1_2_12_18_1 e_1_2_12_110_1 e_1_2_12_137_1 Kerkhof PC (e_1_2_12_36_1) 2008; 159 e_1_2_12_114_1 e_1_2_12_133_1 e_1_2_12_156_1 Levin EC (e_1_2_12_91_1) 2014; 13 e_1_2_12_21_1 e_1_2_12_44_1 e_1_2_12_63_1 e_1_2_12_86_1 e_1_2_12_25_1 e_1_2_12_48_1 e_1_2_12_67_1 Vries A (e_1_2_12_65_1) 2013; 27 e_1_2_12_40_1 e_1_2_12_82_1 e_1_2_12_141_1 e_1_2_12_122_1 e_1_2_12_29_1 Singh J (e_1_2_12_160_1) 2011; 2 e_1_2_12_149_1 e_1_2_12_126_1 e_1_2_12_103_1 e_1_2_12_145_1 e_1_2_12_119_1 e_1_2_12_32_1 e_1_2_12_74_1 e_1_2_12_97_1 e_1_2_12_59_1 e_1_2_12_78_1 e_1_2_12_13_1 Gottlieb A (e_1_2_12_154_1) 2014; 13 e_1_2_12_7_1 e_1_2_12_51_1 e_1_2_12_70_1 e_1_2_12_93_1 e_1_2_12_4_1 Rich P (e_1_2_12_118_1) 2007; 25 e_1_2_12_151_1 e_1_2_12_19_1 e_1_2_12_38_1 e_1_2_12_136_1 e_1_2_12_159_1 e_1_2_12_132_1 e_1_2_12_155_1 Meffert H (e_1_2_12_15_1) 1997; 77 e_1_2_12_41_1 e_1_2_12_87_1 e_1_2_12_106_1 e_1_2_12_129_1 e_1_2_12_22_1 e_1_2_12_64_1 e_1_2_12_45_1 e_1_2_12_26_1 e_1_2_12_68_1 e_1_2_12_83_1 e_1_2_12_60_1 Di Cesare A (e_1_2_12_107_1) 2011; 21 Gottlieb AB (e_1_2_12_55_1) 2015; 14 e_1_2_12_49_1 e_1_2_12_148_1 Yang HZ (e_1_2_12_50_1) 2012; 125 e_1_2_12_102_1 e_1_2_12_125_1 e_1_2_12_144_1 e_1_2_12_52_1 e_1_2_12_33_1 e_1_2_12_75_1 e_1_2_12_56_1 e_1_2_12_37_1 e_1_2_12_79_1 e_1_2_12_14_1 e_1_2_12_90_1 e_1_2_12_8_1 e_1_2_12_10_1 e_1_2_12_94_1 Spadaro A (e_1_2_12_147_1) 1995; 13 e_1_2_12_71_1 Genovese MC (e_1_2_12_121_1) 2007; 34 e_1_2_12_150_1 Edwards CJ (e_1_2_12_140_1) 2013; 65 e_1_2_12_5_1 e_1_2_12_16_1 e_1_2_12_112_1 e_1_2_12_135_1 e_1_2_12_158_1 e_1_2_12_39_1 e_1_2_12_116_1 e_1_2_12_131_1 e_1_2_12_42_1 e_1_2_12_88_1 e_1_2_12_109_1 e_1_2_12_128_1 e_1_2_12_23_1 e_1_2_12_46_1 e_1_2_12_69_1 Singh JA (e_1_2_12_28_1) 2011; 2 e_1_2_12_61_1 e_1_2_12_84_1 e_1_2_12_162_1 e_1_2_12_27_1 Marsland AM (e_1_2_12_98_1) 2006; 1 Wald JM (e_1_2_12_113_1) 2015; 14 e_1_2_12_101_1 e_1_2_12_120_1 e_1_2_12_105_1 e_1_2_12_143_1 Mervic L (e_1_2_12_80_1) 2014; 23 e_1_2_12_124_1 e_1_2_12_30_1 e_1_2_12_53_1 e_1_2_12_99_1 e_1_2_12_117_1 e_1_2_12_34_1 e_1_2_12_57_1 e_1_2_12_11_1 e_1_2_12_72_1 e_1_2_12_95_1 e_1_2_12_9_1 |
| References_xml | – volume: 23 start-page: 1 year: 2009 end-page: 70 article-title: European S3‐guidelines on the systemic treatment of Psoriasis Vulgaris publication-title: J Eur Acad Dermatol Venereol – volume: 66 start-page: 158 year: 2013 end-page: 172 article-title: GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes publication-title: J Clin Epidemiol – volume: 36 start-page: 219 year: 2011 end-page: 232 article-title: Biologic therapy and pregnancy: a systematic literature review publication-title: Acta Reumatol Port – volume: 390 start-page: 40 year: 2017 end-page: 49 article-title: Efficacy and safety of adalimumab versus methotrexate treatment in pediatric patients with severe chronic plaque psoriasis: results from the 16‐week randomized, double‐blind period of a phase 3 study publication-title: Lancet – volume: 367 start-page: 29 year: 2006 end-page: 35 article-title: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double‐blind placebo‐controlled randomised phase III trial publication-title: Lancet – volume: 52 start-page: 189 year: 2005 article-title: Infliximab therapy improves health‐related quality of life in patients with psoriatic arthritis publication-title: J Am Acad Dermatol – volume: 168 start-page: 1325 year: 2013 end-page: 1334 article-title: Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2) publication-title: Br J Dermatol – volume: 2 start-page: CD008794 year: 2011 article-title: Adverse effects of biologics: a network meta‐analysis and Cochrane overview publication-title: Cochrane Database Syst Rev – volume: 148 start-page: 463 year: 2012 end-page: 470 article-title: Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials publication-title: Arch Dermatol – volume: 25 start-page: 184 year: 2008 end-page: 188 article-title: Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India publication-title: Pediatr Dermatol – volume: 28 start-page: 1127 year: 2014 end-page: 1129 article-title: Secukinumab improves the signs and symptoms of moderate‐to‐severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double‐blind, placebo‐controlled, phase 2 dose‐ranging study publication-title: J Eur Acad Dermatol Venereol – volume: 165 start-page: 652 year: 2011 end-page: 660 article-title: Efficacy and safety of briakinumab vs etanercept and placebo in patients with moderate to severe chronic plaque psoriasis publication-title: Br J Dermatol – volume: 65 start-page: 537 year: 2011 end-page: 545 article-title: Psoriasis in the elderly: from the medical board of the National Psoriasis Foundation publication-title: J Am Acad Dermatol – volume: 73 start-page: 1020 year: 2014 end-page: 1026 article-title: Treatment of psoriatic arthritis in a phase 3 randomised, placebo‐ controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor publication-title: Ann Rheum Dis – volume: 119 start-page: 755 year: 1988 end-page: 759 article-title: Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double‐blind comparative trial publication-title: Br J Dermatol – volume: 120 start-page: 211 year: 2003 end-page: 216 article-title: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study publication-title: J Invest Dermatol – volume: 12 start-page: 166 year: 2013 end-page: 174 article-title: Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque‐type psoriasis: results from a phase 3 clinical trial (LOTUS) publication-title: J Drugs Dermatol – volume: 45 start-page: 156 year: 2015 end-page: 162 article-title: Risk of liver injury among methotrexate users: a meta‐analysis of randomised controlled trials publication-title: Semin Arthritis Rheum – volume: 56 start-page: 311 year: 2007 end-page: 315 article-title: A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate‐to‐severe plaque psoriasis publication-title: J Am Acad Dermatol – volume: 168 start-page: 820 year: 2013 end-page: 824 article-title: Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis publication-title: Br J Dermatol – volume: 158 start-page: 558 year: 2008 end-page: 566 article-title: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) publication-title: Br J Dermatol – volume: 56 start-page: 476 year: 2007 end-page: 488 article-title: Adalimumab for long‐term treatment of psoriatic arthritis: forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial publication-title: Arthritis Rheum – volume: 165 start-page: 661 year: 2011 end-page: 668 article-title: Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis publication-title: Br J Dermatol – volume: 27 start-page: 384 year: 2013 end-page: 389 article-title: Efficacy and safety of systemic methotrexate vs acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study publication-title: J Eur Acad Dermatol Venereol – volume: 77 start-page: 137 year: 1997 end-page: 141 article-title: Low‐dose (125 Mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile publication-title: Acta Derm Venereol – volume: 147 start-page: 429 year: 2011 end-page: 436 article-title: Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo‐controlled, double‐blind trial publication-title: Arch Dermatol – volume: 307 start-page: 875 year: 2015 end-page: 883 article-title: Drug safety of systemic treatments for psoriasis: results from the German psoriasis registry PsoBest publication-title: Arch Dermatol Res – volume: 154 start-page: 1161 year: 2006 end-page: 1168 article-title: Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate‐to‐severe psoriasis: a randomized controlled trial publication-title: Br J Dermatol – volume: 171 start-page: 17 year: 2014 end-page: 29 article-title: Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies publication-title: Br J Dermatol – volume: 95 start-page: 57 year: 2015 end-page: 61 article-title: Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study publication-title: Acta Derm Venereol – volume: 25 start-page: 137 year: 2007 end-page: 146 article-title: Nail psoriasis improvement is maintained in patients with moderate to severe psoriasis treated with infliximab publication-title: J Am Acad Dermatol – volume: 172 start-page: 484 year: 2015 end-page: 493 article-title: Secukinumab administration by pre‐filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE) publication-title: Br J Dermatol – volume: 64 start-page: 3156 year: 2012 end-page: 3167 article-title: Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double‐blind, placebo‐controlled study publication-title: Arthritis Rheum – volume: 14 start-page: 888 year: 2015 end-page: 892 article-title: The use of methotrexate, alone or in combination with other therapies, for the treatment of palmoplantar psoriasis publication-title: J Drugs Dermatol – volume: 55 start-page: 517 year: 2006 end-page: 519 article-title: Etanercept for the treatment of psoriasis in the elderly publication-title: J Am Acad Dermatol – volume: 31 start-page: 430 year: 2014 end-page: 439 article-title: A systematic review of systemic medications for pustular psoriasis in pediatrics publication-title: Pediatr Dermatol – volume: 51 start-page: 534 year: 2004 end-page: 542 article-title: Infliximab induction therapy for patients with severe plaque‐ type psoriasis: a randomized, double‐blind, placebo‐controlled trial publication-title: J Am Acad Dermatol – volume: 13 start-page: 1441 year: 2014 end-page: 1448 article-title: Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies publication-title: JDD – volume: 151 start-page: 961 year: 2015 end-page: 969 article-title: Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) publication-title: JAMA Dermatol – volume: 159 start-page: 1177 year: 2008 end-page: 1185 article-title: Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial with open‐label extension publication-title: Br J Dermatol – volume: 101 start-page: 827 year: 2010 end-page: 846 article-title: Treatment of scalp psoriasis: review of the evidence and Delphi consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology publication-title: Actas Dermosifiliogr – volume: 37 start-page: 299 year: 2010 end-page: 310 article-title: Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study publication-title: J Dermatol – volume: 65 start-page: S346 year: 2013 article-title: Long‐term (52‐week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) publication-title: Arthritis Rheum – volume: 152 start-page: 1304 year: 2005 end-page: 1312 article-title: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction publication-title: Br J Dermatol – volume: 25 start-page: 482 year: 2014 end-page: 486 article-title: Tonsillectomy as a treatment for psoriasis: a review publication-title: J Dermatolog Treat – volume: 165 start-page: 1109 year: 2011 end-page: 1117 article-title: Efficacy and safety of infliximab vs methotrexate in patients with moderate‐to‐severe plaque psoriasis: results of an open‐label, active‐controlled, randomized trial (RESTORE1) publication-title: Br J Dermatol – volume: 103 start-page: 936 year: 2012 end-page: 937 article-title: Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab publication-title: Actas Dermosifiliogr – volume: 7 start-page: 104 year: 2011 end-page: 112 article-title: Systematic review: safety and efficacy of anti‐TNF in elderly patients publication-title: Reumatol Clin – volume: 8 start-page: 475 year: 2010 end-page: 476 article-title: Adalimumab level in breast milk of a nursing mother publication-title: Clin Gastroenterol Hepatol – volume: 13 start-page: 342 year: 2014 end-page: 354 article-title: Biologic therapy in erythrodermic and pustular psoriasis publication-title: J Drugs Dermatol – volume: 221 start-page: 321 year: 2010 end-page: 323 article-title: Efficacy of ustekinumab in palmoplantar psoriasis publication-title: Dermatology – volume: 152 start-page: 954 year: 2005 end-page: 960 article-title: Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double‐blind placebo‐controlled trial publication-title: Br J Dermatol – volume: 67 start-page: 459 year: 2012 end-page: 477 article-title: Review of treatment options for psoriasis in pregnant or lactating women: from the medical board of the National Psoriasis Foundation publication-title: J Am Acad Dermatol – volume: 29 start-page: 468 year: 2015 end-page: 473 article-title: Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study publication-title: J Eur Acad Dermatol Venereol – volume: 131 start-page: 791 year: 1995 end-page: 795 article-title: Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy publication-title: Arch Dermatol – volume: 24 start-page: 179 year: 2013 end-page: 187 article-title: Investigator‐initiated, open‐label trial of ustekinumab for the treatment of moderate‐to‐severe palmoplantar psoriasis publication-title: J Dermatolog Treat – volume: 37 start-page: 1221 year: 2010 end-page: 1227 article-title: Patient‐reported outcomes in a randomized trial of etanercept in psoriatic arthritis publication-title: J Rheumatol – volume: 73 start-page: 48 year: 2014 end-page: 55 article-title: Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24‐week results of a phase 3 double‐blind randomised placebo‐controlled study (RAPID‐PsA) publication-title: Ann Rheum Dis – volume: 73 start-page: 400 year: 2015 end-page: 409 article-title: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial publication-title: J Am Acad Dermatol – volume: 53 start-page: 464 year: 2014 end-page: 466 article-title: Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis publication-title: Int J Dermatol – volume: 13 start-page: 589 year: 1995 end-page: 593 article-title: Comparison of cyclosporin a and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study publication-title: Clin Exp Rheumatol – volume: 362 start-page: 118 year: 2010 end-page: 128 article-title: Comparison of ustekinumab and etanercept for moderate‐to‐severe psoriasis publication-title: N Engl J Med – volume: 39 start-page: 265 year: 2012 end-page: 268 article-title: Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community‐based hospital publication-title: J Dermatol – volume: 366 start-page: 1367 year: 2005 end-page: 1374 article-title: Infliximab induction and maintenance therapy for moderate‐ to‐severe psoriasis: a phase III, multicentre, double‐blind trial publication-title: Lancet – volume: 41 start-page: 1039 year: 2014 end-page: 1046 article-title: Secukinumab efficacy and safety in Japanese patients with moderate‐to‐severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo‐controlled, phase 3 study publication-title: J Dermatol – volume: 66 start-page: 173 year: 2013 end-page: 183 article-title: GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles‐continuous outcomes publication-title: J Clin Epidemiol – volume: 371 start-page: 1665 year: 2008 end-page: 1674 article-title: Efficacy and safety of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with psoriasis: 76‐week results from a randomised, double‐blind, placebo‐controlled trial (PHOENIX 1) publication-title: Lancet – volume: 228 start-page: 107 year: 2014 end-page: 111 article-title: Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two greek patients from the psoriasis hospital‐based clinic publication-title: Dermatology – volume: 12 start-page: 51 year: 2011 end-page: 62 article-title: Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co‐morbidities: subanalysis of results from a randomized, double‐blind, placebo‐controlled, phase III trial publication-title: Am J Clin Dermatol – volume: 56 start-page: 598 year: 2007 end-page: 603 article-title: A randomized, open‐label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis publication-title: J Am Acad Dermatol – volume: 33 start-page: 163 year: 2015 end-page: 177 article-title: Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost‐effectiveness analysis publication-title: Pharmacoeconomics – volume: 357 start-page: 1842 year: 2001 end-page: 1847 article-title: Efficacy and safety of infliximab monotherapy for plaque‐type psoriasis: a randomized trial publication-title: Lancet – volume: 44 start-page: 695 year: 2005 end-page: 696 article-title: Survival and safety of treatment with infliximab in the elderly population publication-title: Rheumatology (Oxford) – volume: 73 start-page: 990 year: 2014 end-page: 999 article-title: Efficacy and safety of the anti‐IL‐12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non‐biological and biological anti‐tumour necrosis factor therapy: 6‐month and 1‐year results of the phase 3, multicentre, double‐Blind, placebo‐controlled, randomised PSUMMIT 2 trial publication-title: Ann Rheum Dis – volume: 70 start-page: 712 year: 2011 end-page: 714 article-title: Etanercept plus cyclosporine versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study publication-title: Ann Rheum Dis – volume: 67 start-page: 86 year: 2012 end-page: 92 article-title: Moderate to severe plaque psoriasis with scalp involvement: a randomized, double‐blind, placebo‐controlled study of etanercept publication-title: J Am Acad Dermatol – volume: 6 start-page: 125 year: 2016 end-page: 142 article-title: Systemic treatment of pediatric psoriasis: a review publication-title: Dermatol Ther (Heidelb) – volume: 163 start-page: 1116 year: 2010 end-page: 1118 article-title: Ustekinumab in the treatment of palmoplantar pustulosis publication-title: Br J Dermatol – volume: 51 start-page: 1368 year: 2012 end-page: 1377 article-title: A randomized placebo‐controlled trial of methotrexate in psoriatic arthritis publication-title: Rheumatology (Oxford) – volume: 65 start-page: 379 year: 2006 end-page: 384 article-title: Long term safety of etanercept in elderly subjects with rheumatic diseases publication-title: Ann Rheum Dis – volume: 43 start-page: 1011 year: 2016 end-page: 1017 article-title: Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52‐week analysis from phase III open‐label multicenter Japanese study publication-title: J Dermatol – volume: 58 start-page: 106 year: 2008 end-page: 115 article-title: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial publication-title: J Am Acad Dermatol – volume: 73 start-page: 594 year: 2015 end-page: 603 article-title: Ustekinumab in adolescent patients age 12 to 17 years with moderate‐to‐severe plaque psoriasis: results of the randomized phase 3 CADMUS study publication-title: J Am Acad Dermatol – volume: 29 start-page: 353 year: 2015 end-page: 360 article-title: Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study publication-title: J Eur Acad Dermatol Venereol – volume: 386 start-page: 1137 year: 2015 end-page: 1146 article-title: Secukinumab, a human anti‐interleukin‐17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double‐blind, placebo‐controlled, phase 3 trial publication-title: Lancet – volume: 39 start-page: 242 year: 2012 end-page: 252 article-title: Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis:vlong‐term results from a phase 2/3 clinical trial publication-title: J Dermatol – volume: 139 start-page: 1627 year: 2003 end-page: 1632 article-title: A randomized trial of etanercept as monotherapy for psoriasis publication-title: Arch Dermatol – volume: 14 start-page: 821 year: 2015 end-page: 833 article-title: Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials publication-title: J Drugs Dermatol – volume: 34 start-page: 295 year: 2009 end-page: 298 article-title: Methotrexate treatment in 13 children with severe plaque psoriasis publication-title: Clin Exp Dermatol – volume: 28 start-page: 1670 year: 2014 end-page: 1675 article-title: Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial publication-title: J Eur Acad Dermatol Venereol – volume: 143 start-page: 719 year: 2007 end-page: 726 article-title: Long‐term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis publication-title: Arch Dermatol – volume: 106 start-page: 477 year: 2015 end-page: 482 article-title: Risk of reactivation of hepatitis b virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database publication-title: Actas Dermosifiliogr – volume: 373 start-page: 633 year: 2009 end-page: 640 article-title: Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double‐blind, placebo‐controlled, crossover trial publication-title: Lancet – volume: 371 start-page: 326 year: 2014 end-page: 338 article-title: Secukinumab in plaque psoriasis‐results of two phase 3 trials publication-title: N Engl J Med – volume: 142 start-page: 1000 year: 2006 end-page: 1004 article-title: Low‐dose acitretin is associated with fewer adverse events than high‐dose acitretin in the treatment of psoriasis publication-title: Arch Dermatol – volume: 26 start-page: 458 year: 1992 end-page: 461 article-title: A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis publication-title: J Am Acad Dermatol – volume: 17 start-page: 9 year: 2006 end-page: 17 article-title: Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy publication-title: J Dermatolog Treat – volume: 33 start-page: 530 year: 2016 end-page: 535 article-title: Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis publication-title: Pediatr Dermatol – volume: 68 start-page: 702 year: 2009 end-page: 709 article-title: Adalimumab for long‐term treatment of psoriatic arthritis: 2‐year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT) publication-title: Ann Rheum Dis – volume: 358 start-page: 241 year: 2008 end-page: 251 article-title: Etanercept treatment for children and adolescents with plaque psoriasis publication-title: N Engl J Med – volume: 72 start-page: 261 year: 2015 end-page: 275 article-title: Effect of tonsillectomy on psoriasis: a systematic review publication-title: J Am Acad Dermatol – volume: 29 start-page: 210 year: 2009 end-page: 214 article-title: Serum levels of IL‐17 and IL‐22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized‐controlled trial publication-title: J Clin Immunol – volume: 29 start-page: 399 year: 2010 end-page: 403 article-title: Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease‐modifying antirheumatic drugs publication-title: Clin Rheumatol – volume: 65 start-page: S132 year: 2013 article-title: Long‐term (52‐week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skininvolvement (PALACE 3) publication-title: Arthritis Rheum – volume: 371 start-page: 1675 year: 2008 end-page: 1684 article-title: Efficacy and safety of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with psoriasis: 52‐week results from a randomised, double‐blind, placebo‐controlled trial (PHOENIX 2) publication-title: Lancet – volume: 336 start-page: 924 year: 2008 end-page: 926 article-title: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations publication-title: BMJ – volume: 29 start-page: 1082 year: 2015 end-page: 1090 article-title: Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) publication-title: J Eur Acad Dermatol Venereol – volume: 12 start-page: 193 year: 2012 end-page: 207 article-title: Anti‐TNF drugs in patients with hepatitis b or c virus infection: safety and clinical management publication-title: Expert Opin Biol Ther – volume: 35 start-page: 717 year: 2010 end-page: 722 article-title: Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo‐controlled trial to determine efficacy, safety and quality of life publication-title: Clin Exp Dermatol – volume: 16 issue: Suppl 1 year: 2010 article-title: Consenso Latinoamericano de Psoriasis, Guías de Tratamiento publication-title: Dermatol Argent – volume: 50 start-page: 2264 year: 2004 end-page: 2272 article-title: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression publication-title: Arthritis Rheum – volume: 27 start-page: 305 year: 2013 end-page: 311 article-title: Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study publication-title: J Eur Acad Dermatol Venereol – volume: 163 start-page: 61 year: 2012 end-page: 66 article-title: Safety and efficacy of adalimumab in the treatment of moderate to severe palmo‐plantar psoriasis: an open label study publication-title: Clin Ter – volume: 349 start-page: 2014 year: 2003 end-page: 2022 article-title: Etanercept as monotherapy in patients with psoriasis publication-title: N Engl J Med – volume: 27 start-page: 2 year: 2013 end-page: 2 article-title: An independent prospective randomized controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in ‘high need’ patients with moderate to severe chronic plaque type psoriasis publication-title: J Eur Acad Dermatol Venereol – volume: 18 start-page: 655 year: 1988 end-page: 662 article-title: Acitretin improves psoriasis in a dose‐dependent fashion publication-title: J Am Acad Dermatol – volume: 2013 start-page: 347520 year: 2013 article-title: Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review publication-title: Int J Rheumatol – volume: 27 start-page: 1366 year: 2013 end-page: 1374 article-title: Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate‐severe psoriasis in Spain. BIOBADADERM registry publication-title: J Eur Acad Dermatol Venereol – volume: 25 start-page: 1402 year: 2011 end-page: 1408 article-title: Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study publication-title: J Eur Acad Dermatol Venereol – volume: 55 start-page: 598 year: 2006 end-page: 606 article-title: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double‐blind, randomized controlled trial and open label extension study publication-title: J Am Acad Dermatol – volume: 168 start-page: 412 year: 2013 end-page: 421 article-title: Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study publication-title: Br J Dermatol – volume: 159 start-page: 704 year: 2008 end-page: 710 article-title: Infliximab improves health‐related quality of life in the presence of comorbidities among patients with moderate‐to‐severe psoriasis publication-title: Br J Dermatol – volume: 168 start-page: 844 year: 2013 end-page: 854 article-title: Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up publication-title: Br J Dermatol – volume: 42 start-page: 479 year: 2015 end-page: 488 article-title: Longterm (52‐Week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis publication-title: J Rheumatol – volume: 164 start-page: 434 year: 2011 end-page: 441 article-title: Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy publication-title: Br J Dermatol – volume: 356 start-page: 385 year: 2000 end-page: 390 article-title: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial publication-title: Lancet – volume: 153 start-page: 1192 year: 2005 end-page: 1199 article-title: Patient‐reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial publication-title: Br J Dermatol – volume: 125 start-page: 1845 year: 2012 end-page: 1851 article-title: Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled multicenter trial publication-title: Chin Med J (Engl) – volume: 13 start-page: 1749 year: 2014 end-page: 1762 article-title: How safe is infliximab therapy during pregnancy and lactation in inflammatory owel disease? publication-title: Expert Opin Drug Saf – volume: 158 start-page: 549 year: 2008 end-page: 557 article-title: Impact of adalimumab treatment on health‐related quality of life and other patient‐reported outcomes: results from a 16‐week randomized controlled trial in patients with moderate to severe plaque psoriasis publication-title: Br J Dermatol – volume: 324 start-page: 277 year: 1991 end-page: 284 article-title: Cyclosporine for plaque‐type psoriasis: results of a multidose, double‐blind trial publication-title: N Engl J Med – volume: 48 start-page: 829 year: 2003 end-page: 835 article-title: Infliximab monotherapy provides rapid and sustained benefit for plaque‐type psoriasis publication-title: J Am Acad Dermatol – volume: 29 start-page: 425 year: 2015 end-page: 437 article-title: Systemic treatments in paediatric psoriasis: a systematic evidence‐based update publication-title: J Eur Acad Dermatol Venereol – year: 2012 – volume: 34 start-page: 435 year: 2007 end-page: 440 article-title: Comparison of the efficacy of local narrowband ultraviolet B (NB‐UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis publication-title: J Dermatol – volume: 52 start-page: 1227 year: 2005 end-page: 1236 article-title: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) publication-title: Arthritis Rheum – volume: 23 start-page: 1143 year: 2010 end-page: 1152 article-title: Psoriasis relapse evaluation with week‐end cyclosporine a treatment: results of a randomized, double‐blind, multicenter study publication-title: Int J Immunopathol Pharmacol – volume: 168 start-page: 402 year: 2013 end-page: 411 article-title: Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study publication-title: Br J Dermatol – volume: 63 start-page: 762 year: 2010 end-page: 768 article-title: Long‐term etanercept in pediatric patients with plaque psoriasis publication-title: J Am Acad Dermatol – volume: 34 start-page: 1040 year: 2007 end-page: 1050 article-title: Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy publication-title: J Rheumatol – volume: 63 start-page: 154 year: 2011 end-page: 163 article-title: Efficacy and safety of ustekinumab for the treatment of moderateto‐ severe psoriasis: a phase III, randomized, placebo‐controlled trial in Taiwanese and Korean patients (PEARL) publication-title: J Dermatol Sci – volume: 382 start-page: 780 year: 2013 end-page: 789 article-title: Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double‐blind, placebo‐controlled PSUMMIT 1 trial publication-title: Lancet – volume: 1 start-page: CD001433 year: 2006 article-title: Interventions for chronic palmoplantar pustulosis publication-title: Cochrane Database Syst Rev – volume: 171 start-page: 485 year: 2014 end-page: 491 article-title: Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients publication-title: Br J Dermatol – volume: 23 start-page: 27 year: 2014 end-page: 31 article-title: Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics publication-title: Acta Dermatovenerol Alp Pannonica Adriat – volume: 27 start-page: 125 year: 2013 end-page: 128 article-title: Patient‐reported outcomes in moderate‐to‐severe plaque psoriasis with scalp involvement: results from a randomized, double‐blind, placebo‐controlled study of etanercept publication-title: J Eur Acad Dermatol Venereol – volume: 373 start-page: 1329 year: 2015 end-page: 1339 article-title: Secukinumab inhibition of interleukin‐17A in patients with psoriatic arthritis publication-title: N Engl J Med – volume: 21 start-page: 993 year: 2011 end-page: 994 article-title: Rapid response of scalp psoriasis to ustekinumab publication-title: Eur J Dermatol – volume: 59 start-page: 40 year: 2010 end-page: 49 article-title: Infliximab monotherapy in Japanese patients with moderate‐to‐severe plaque psoriasis and psoriatic arthritis: a randomized, double‐blind, placebo‐controlled multicenter trial publication-title: J Dermatol Sci – volume: 67 start-page: 189 year: 2008 end-page: 194 article-title: Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 25 start-page: 1080 year: 2011 end-page: 1084 article-title: Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one‐blind, randomized study publication-title: J Eur Acad Dermatol Venereol – volume: 73 start-page: 1689 year: 2014 end-page: 1694 article-title: Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long‐term extension of a randomised, placebo‐controlled trial (the GO‐REVEAL study) publication-title: Ann Rheum Dis – volume: 64 start-page: 1035 year: 2011 end-page: 1050 article-title: The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta‐analysis of randomized controlled trials publication-title: J Am Acad Dermatol – volume: 64 start-page: 2504 year: 2012 end-page: 2517 article-title: Golimumab in psoriatic arthritis: one‐year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo‐controlled trial publication-title: Arthritis Rheum – ident: e_1_2_12_66_1 doi: 10.1056/NEJMoa0810652 – volume: 23 start-page: 27 year: 2014 ident: e_1_2_12_80_1 article-title: Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics publication-title: Acta Dermatovenerol Alp Pannonica Adriat contributor: fullname: Mervic L – ident: e_1_2_12_105_1 doi: 10.1111/jdv.12553 – ident: e_1_2_12_20_1 doi: 10.1111/j.1365-2230.2009.03693.x – ident: e_1_2_12_22_1 doi: 10.1111/j.1365-2133.2007.08315.x – volume: 163 start-page: 61 year: 2012 ident: e_1_2_12_111_1 article-title: Safety and efficacy of adalimumab in the treatment of moderate to severe palmo‐plantar psoriasis: an open label study publication-title: Clin Ter contributor: fullname: Richetta AG – ident: e_1_2_12_38_1 doi: 10.1111/j.1365-2133.2011.10418.x – ident: e_1_2_12_151_1 doi: 10.1016/j.jaad.2006.09.002 – ident: e_1_2_12_92_1 doi: 10.1111/jdv.12749 – volume: 2 start-page: CD008794 year: 2011 ident: e_1_2_12_160_1 article-title: Adverse effects of biologics: a network meta‐analysis and Cochrane overview publication-title: Cochrane Database Syst Rev contributor: fullname: Singh J – ident: e_1_2_12_86_1 doi: 10.1016/j.jaad.2015.07.002 – ident: e_1_2_12_34_1 doi: 10.2340/00015555-1845 – ident: e_1_2_12_63_1 doi: 10.1111/bjd.12214 – ident: e_1_2_12_115_1 doi: 10.1111/jdv.12343 – ident: e_1_2_12_17_1 doi: 10.1046/j.1523-1747.2003.12040.x – ident: e_1_2_12_123_1 doi: 10.1136/ard.2008.092767 – ident: e_1_2_12_99_1 doi: 10.3109/09546634.2012.672710 – ident: e_1_2_12_108_1 doi: 10.1159/000357030 – ident: e_1_2_12_106_1 doi: 10.1111/j.1468-3083.2011.04394.x – ident: e_1_2_12_5_1 – volume: 12 start-page: 166 year: 2013 ident: e_1_2_12_62_1 article-title: Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque‐type psoriasis: results from a phase 3 clinical trial (LOTUS) publication-title: J Drugs Dermatol contributor: fullname: Zhu X – ident: e_1_2_12_103_1 doi: 10.1111/bjd.12150 – ident: e_1_2_12_68_1 doi: 10.1007/s40273-014-0226-y – ident: e_1_2_12_54_1 doi: 10.1111/bjd.12112 – ident: e_1_2_12_70_1 – ident: e_1_2_12_49_1 doi: 10.1016/j.jdermsci.2010.04.014 – ident: e_1_2_12_53_1 doi: 10.1111/jdv.12751 – ident: e_1_2_12_116_1 doi: 10.1111/jdv.12004 – ident: e_1_2_12_94_1 doi: 10.3109/09546634.2013.848258 – ident: e_1_2_12_18_1 doi: 10.1155/2013/347520 – ident: e_1_2_12_13_1 doi: 10.1111/j.1468-3083.2012.04644.x – ident: e_1_2_12_14_1 doi: 10.1056/NEJM199101313240501 – ident: e_1_2_12_8_1 doi: 10.1016/j.jclinepi.2012.08.001 – ident: e_1_2_12_39_1 doi: 10.1111/j.1365-2133.2011.10419.x – ident: e_1_2_12_72_1 doi: 10.1016/j.jaad.2010.05.014 – ident: e_1_2_12_132_1 doi: 10.1016/S0140-6736(15)61134-5 – ident: e_1_2_12_7_1 – volume: 14 start-page: 888 year: 2015 ident: e_1_2_12_113_1 article-title: The use of methotrexate, alone or in combination with other therapies, for the treatment of palmoplantar psoriasis publication-title: J Drugs Dermatol contributor: fullname: Wald JM – ident: e_1_2_12_150_1 doi: 10.1080/09546630500472838 – ident: e_1_2_12_56_1 doi: 10.1056/NEJMoa1314258 – ident: e_1_2_12_124_1 doi: 10.1136/annrheumdis-2013-203696 – ident: e_1_2_12_152_1 doi: 10.1111/jdv.12585 – ident: e_1_2_12_130_1 doi: 10.1093/rheumatology/kes001 – ident: e_1_2_12_155_1 doi: 10.1517/14712598.2012.646986 – ident: e_1_2_12_88_1 doi: 10.1007/s13555-016-0117-6 – volume: 14 start-page: 821 year: 2015 ident: e_1_2_12_55_1 article-title: Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials publication-title: J Drugs Dermatol contributor: fullname: Gottlieb AB – ident: e_1_2_12_27_1 doi: 10.1016/j.jaad.2006.05.027 – ident: e_1_2_12_78_1 doi: 10.1016/j.jaad.2011.07.039 – ident: e_1_2_12_134_1 doi: 10.1016/S0140-6736(13)60594-2 – ident: e_1_2_12_31_1 doi: 10.1111/j.1365-2133.2005.06948.x – ident: e_1_2_12_119_1 doi: 10.1111/j.1468-3083.2010.03927.x – ident: e_1_2_12_100_1 doi: 10.1111/ijd.12511 – ident: e_1_2_12_146_1 doi: 10.1136/ard.2010.130864 – ident: e_1_2_12_35_1 doi: 10.1001/archderm.143.6.719 – ident: e_1_2_12_159_1 doi: 10.1016/j.ad.2015.01.010 – ident: e_1_2_12_89_1 doi: 10.1016/S0140-6736(17)31189-3 – ident: e_1_2_12_24_1 doi: 10.1111/j.1346-8138.2009.00748.x – volume: 25 start-page: 137 year: 2007 ident: e_1_2_12_118_1 article-title: Nail psoriasis improvement is maintained in patients with moderate to severe psoriasis treated with infliximab publication-title: J Am Acad Dermatol contributor: fullname: Rich P – ident: e_1_2_12_142_1 doi: 10.1136/annrheumdis-2013-205056 – ident: e_1_2_12_137_1 doi: 10.1136/annrheumdis-2013-204902 – ident: e_1_2_12_141_1 – volume: 77 start-page: 137 year: 1997 ident: e_1_2_12_15_1 article-title: Low‐dose (125 Mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile publication-title: Acta Derm Venereol doi: 10.2340/0001555577137141 contributor: fullname: Meffert H – ident: e_1_2_12_16_1 doi: 10.1001/archderm.1995.01690190043008 – volume: 65 start-page: S132 year: 2013 ident: e_1_2_12_140_1 article-title: Long‐term (52‐week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skininvolvement (PALACE 3) publication-title: Arthritis Rheum contributor: fullname: Edwards CJ – ident: e_1_2_12_10_1 doi: 10.1111/j.1365-2133.1988.tb03499.x – volume: 2 start-page: CD008794 year: 2011 ident: e_1_2_12_28_1 article-title: Adverse effects of biologics: a network meta‐analysis and Cochrane overview publication-title: Cochrane Database Syst Rev contributor: fullname: Singh JA – ident: e_1_2_12_71_1 doi: 10.1136/ard.2005.035287 – ident: e_1_2_12_46_1 doi: 10.1016/j.jaad.2004.02.021 – ident: e_1_2_12_74_1 doi: 10.1093/rheumatology/keh562 – ident: e_1_2_12_40_1 doi: 10.1016/j.jaad.2011.07.034 – ident: e_1_2_12_156_1 doi: 10.1001/archdermatol.2011.2768 – ident: e_1_2_12_12_1 doi: 10.1001/archderm.142.8.1000 – volume: 159 start-page: 1177 year: 2008 ident: e_1_2_12_36_1 article-title: Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial with open‐label extension publication-title: Br J Dermatol contributor: fullname: Kerkhof PC – ident: e_1_2_12_148_1 doi: 10.1067/mjd.2003.307 – ident: e_1_2_12_87_1 doi: 10.1111/pde.12940 – ident: e_1_2_12_101_1 doi: 10.1159/000320961 – ident: e_1_2_12_41_1 doi: 10.1111/j.1365-2133.2011.10615.x – volume: 16 issue: 1 year: 2010 ident: e_1_2_12_2_1 article-title: Consenso Latinoamericano de Psoriasis, Guías de Tratamiento publication-title: Dermatol Argent contributor: fullname: Sociedad Latinoamericana de Psoriasis – ident: e_1_2_12_47_1 doi: 10.1016/j.jaad.2006.07.017 – ident: e_1_2_12_97_1 doi: 10.1111/pde.12351 – volume: 34 start-page: 1040 year: 2007 ident: e_1_2_12_121_1 article-title: Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy publication-title: J Rheumatol contributor: fullname: Genovese MC – volume: 65 start-page: S346 year: 2013 ident: e_1_2_12_138_1 article-title: Long‐term (52‐week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) publication-title: Arthritis Rheum contributor: fullname: Cutolo M – ident: e_1_2_12_32_1 doi: 10.1056/NEJMoa030409 – ident: e_1_2_12_58_1 doi: 10.1111/j.1346-8138.2011.01347.x – ident: e_1_2_12_79_1 doi: 10.1517/14740338.2014.959489 – ident: e_1_2_12_82_1 doi: 10.1016/j.jaad.2010.04.004 – volume: 13 start-page: 589 year: 1995 ident: e_1_2_12_147_1 article-title: Comparison of cyclosporin a and methotrexate in the treatment of psoriatic arthritis: a one‐year prospective study publication-title: Clin Exp Rheumatol contributor: fullname: Spadaro A – ident: e_1_2_12_144_1 doi: 10.1002/art.34627 – ident: e_1_2_12_60_1 doi: 10.1016/S0140-6736(08)60726-6 – ident: e_1_2_12_73_1 doi: 10.1016/j.jaad.2006.02.010 – ident: e_1_2_12_157_1 doi: 10.1111/jdv.12011 – ident: e_1_2_12_61_1 doi: 10.1016/j.jdermsci.2011.05.005 – volume: 125 start-page: 1845 year: 2012 ident: e_1_2_12_50_1 article-title: Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled multicenter trial publication-title: Chin Med J (Engl) contributor: fullname: Yang HZ – volume: 21 start-page: 993 year: 2011 ident: e_1_2_12_107_1 article-title: Rapid response of scalp psoriasis to ustekinumab publication-title: Eur J Dermatol doi: 10.1684/ejd.2011.1499 contributor: fullname: Di Cesare A – ident: e_1_2_12_162_1 doi: 10.1007/s00403-015-1593-8 – ident: e_1_2_12_6_1 doi: 10.1111/j.1468-3083.2009.03389.x – ident: e_1_2_12_122_1 doi: 10.1002/art.22379 – ident: e_1_2_12_129_1 doi: 10.1016/j.jaad.2004.10.766 – ident: e_1_2_12_25_1 doi: 10.2165/11530640-000000000-00000 – ident: e_1_2_12_77_1 doi: 10.1111/bjd.13060 – ident: e_1_2_12_104_1 doi: 10.1111/j.1346-8138.2007.00306.x – ident: e_1_2_12_33_1 doi: 10.1111/j.1365-2133.2005.06688.x – volume: 1 start-page: CD001433 year: 2006 ident: e_1_2_12_98_1 article-title: Interventions for chronic palmoplantar pustulosis publication-title: Cochrane Database Syst Rev contributor: fullname: Marsland AM – volume: 13 start-page: 1441 year: 2014 ident: e_1_2_12_154_1 article-title: Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies publication-title: JDD contributor: fullname: Gottlieb A – ident: e_1_2_12_29_1 doi: 10.1001/jamadermatol.2015.0718 – ident: e_1_2_12_4_1 doi: 10.1136/bmj.39489.470347.AD – ident: e_1_2_12_84_1 doi: 10.1111/j.1525-1470.2008.00629.x – ident: e_1_2_12_95_1 doi: 10.1016/j.jaad.2014.10.013 – ident: e_1_2_12_120_1 doi: 10.1016/j.ad.2011.12.018 – ident: e_1_2_12_11_1 doi: 10.1016/S0190-9622(88)70086-9 – ident: e_1_2_12_42_1 doi: 10.1016/S0140-6736(05)67566-6 – ident: e_1_2_12_125_1 doi: 10.1002/art.20335 – ident: e_1_2_12_135_1 doi: 10.1136/annrheumdis-2013-204655 – ident: e_1_2_12_57_1 doi: 10.1111/1346-8138.12668 – ident: e_1_2_12_102_1 doi: 10.1111/j.1365-2133.2010.09897.x – ident: e_1_2_12_112_1 doi: 10.1111/j.1468-3083.2011.03984.x – ident: e_1_2_12_136_1 doi: 10.1002/art.34436 – ident: e_1_2_12_128_1 doi: 10.1002/art.20967 – ident: e_1_2_12_52_1 doi: 10.1111/bjd.12110 – ident: e_1_2_12_126_1 doi: 10.1016/S0140-6736(00)02530-7 – ident: e_1_2_12_45_1 doi: 10.1111/j.1365-2133.2008.08727.x – ident: e_1_2_12_21_1 doi: 10.1111/j.1365-2133.2007.08236.x – ident: e_1_2_12_48_1 doi: 10.1111/j.1365-2133.2006.07237.x – ident: e_1_2_12_26_1 doi: 10.1016/j.jaad.2007.09.010 – ident: e_1_2_12_161_1 doi: 10.1016/j.jaad.2010.09.734 – ident: e_1_2_12_143_1 doi: 10.3899/jrheum.140647 – ident: e_1_2_12_85_1 doi: 10.1111/j.1365-2230.2008.02907.x – ident: e_1_2_12_96_1 doi: 10.1111/1346-8138.13306 – ident: e_1_2_12_81_1 doi: 10.1016/j.cgh.2009.11.023 – ident: e_1_2_12_114_1 doi: 10.1111/jdv.12359 – ident: e_1_2_12_153_1 doi: 10.1111/bjd.12404 – ident: e_1_2_12_158_1 doi: 10.1111/bjd.12941 – ident: e_1_2_12_43_1 doi: 10.1016/S0140-6736(00)04954-0 – ident: e_1_2_12_69_1 doi: 10.1016/j.reuma.2010.02.001 – ident: e_1_2_12_117_1 doi: 10.1001/archdermatol.2010.384 – volume: 36 start-page: 219 year: 2011 ident: e_1_2_12_76_1 article-title: Biologic therapy and pregnancy: a systematic literature review publication-title: Acta Reumatol Port contributor: fullname: Bogas M – ident: e_1_2_12_127_1 doi: 10.3899/jrheum.091093 – ident: e_1_2_12_67_1 doi: 10.1016/j.jaad.2015.05.013 – volume: 13 start-page: 342 year: 2014 ident: e_1_2_12_91_1 article-title: Biologic therapy in erythrodermic and pustular psoriasis publication-title: J Drugs Dermatol contributor: fullname: Levin EC – ident: e_1_2_12_37_1 doi: 10.1016/S0140-6736(05)67763-X – ident: e_1_2_12_44_1 doi: 10.1111/j.1365-2133.2005.06510.x – ident: e_1_2_12_83_1 doi: 10.1056/NEJMoa066886 – ident: e_1_2_12_145_1 doi: 10.1007/s10067-009-1340-7 – ident: e_1_2_12_23_1 doi: 10.1016/j.semarthrit.2015.05.003 – ident: e_1_2_12_19_1 doi: 10.1177/039463201002300418 – ident: e_1_2_12_30_1 doi: 10.1001/archderm.139.12.1627 – volume: 27 start-page: 2 year: 2013 ident: e_1_2_12_65_1 article-title: An independent prospective randomized controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in ‘high need’ patients with moderate to severe chronic plaque type psoriasis publication-title: J Eur Acad Dermatol Venereol contributor: fullname: Vries A – ident: e_1_2_12_131_1 doi: 10.1056/NEJMoa1412679 – ident: e_1_2_12_109_1 doi: 10.1111/j.1346-8138.2011.01312.x – ident: e_1_2_12_90_1 – ident: e_1_2_12_75_1 doi: 10.1136/ard.2007.072967 – ident: e_1_2_12_133_1 doi: 10.1016/S0140-6736(09)60140-9 – ident: e_1_2_12_149_1 doi: 10.1111/j.1365-2133.2010.10139.x – ident: e_1_2_12_93_1 doi: 10.1016/0190-9622(92)70072-N – ident: e_1_2_12_51_1 doi: 10.1111/bjd.13348 – ident: e_1_2_12_64_1 doi: 10.1007/s10875-008-9233-0 – ident: e_1_2_12_3_1 – ident: e_1_2_12_110_1 doi: 10.1016/j.ad.2010.09.001 – ident: e_1_2_12_139_1 – ident: e_1_2_12_9_1 doi: 10.1016/j.jclinepi.2012.01.012 – ident: e_1_2_12_59_1 doi: 10.1016/S0140-6736(08)60725-4 |
| SSID | ssj0013214 |
| Score | 2.3619196 |
| SecondaryResourceType | review_article |
| Snippet | This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 4 |
| SubjectTerms | Clinical medicine Clinical practice guidelines Clinical trials Patients Phototherapy Psoriasis Quality assessment Quality of life |
| Title | Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO – Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society) |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fijd.14471 https://www.ncbi.nlm.nih.gov/pubmed/31282026 https://www.proquest.com/docview/2252957809 https://search.proquest.com/docview/2253828063 |
| Volume | 58 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LSsNAFB20C3Hj-1GtchUXdRFIOs1jcFVsa5VqC63gLkxmEqhIIsbu_Qc_wv_yS7wzeZAqguAukMyDuY-5M-feE0LOHI_ZwqTCkA51DcXIZbC2InJto2NwTO6xSCG6g4l79-B1e4om56Kohcn4IcoLN2UZ2l8rA-dBWjHy2aNUyKSuH8dTgi7foOMKgpDxeqsrQIYxRM4qpLJ4ypaLe9GPAHMxXtUbTn_9X1PdIGt5nAmdTDE2yVIYb5GV2xxJ3yYfQxRJDAVgAzk_6BOM87IpuJorBiyVFQ9JDBgnQsZuPhMwLbLTIYlgnCaoxOkshclo2BlPRvD59g46G1RyCXqchOfjcJBhpUXz2ywqfWXZpOc75L7fm14OjPynDYagaM9GYGHfDgYtkcupIv8Tjs1QB6xIBG3JhWOFYSgidBxSWBj-mJFEZfF41GIeN1uC7pJanMThPgF0gDKyhR0oVjomg8Ayqe26puQKG22zOjktxOc_Z9wcfnGmwSX39ZLXSaMQrJ-bZ-qjE2sx9FUm9nFSvkbDUmgJj8Nkrr-hnsKdaZ3sZQpRjkJxV2_h6bVOmlruvw_vX9909cPB3z89JKsYlrEszbBBaq8v8_CILKdyfqx1_At8dP1r |
| link.rule.ids | 315,782,786,1408,27934,27935,46065,46489 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NatwwEB6aLaS5JGnaNNv8TUsP6cFgr_wnyCV0k-62m2Rht9CbkSUbtgQ7xNl73iEPkffqk2RGtpdNS6GQm8GWRmh-9Ekz-gzwKYxloF2hHROKyGFGLkf6TOTqU2AIXRXLnDO6g0l08TPunzJNznF7F6bmh1gcuLFn2HjNDs4H0ktePvtlODXJF8hf-qEfs00LMV7KIdTM3nwIKAlFNLxCXMezaPp0NfoLYj5FrHbJOdt43mA3Yb2BmnhS28ZreJEVW7B63iTT38DDiLRSYJuzwYYi9ArHzc0p_DpnEiwujMeyQIKKWBOczzRO2wJ1LHMcVyXZcTWrcHI5OhlPLvH33T3aglCjDFo5pWrkKDTZUoujP0ax1FddUPr5Lfw4O51-GTjNfxscLcilndSjvkPCLXmkBPP_6TCQZAZerlPfKB16WZbpnGKH0R4hIDc3ZC-xynsyVm5Pi23oFGWR7QBSDDR5oIOUiemkSVPPFUEUuUZxetSXXfjY6i-5ruk5knZbQ1Oe2Cnvwl6r2aTx0CqhONaTFK5c6uPD4jX5FidMVJGVc_uNiDn1LLrwrraIhRRBC3uPNrBdOLKK_7f4ZPitbx_e__-nh_BqMD0fJaPhxfddWCOUJuuqwz3o3N7Ms31Yqcz8wBr8I3qLAaM |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NTtwwEB61VEK9AC0tLKXtFHGgh0jJOn8WJ9RlC-0CkZZKvUWOHUtbVQki7J134CF4L56kM06yWlpVqtRbpMQey_Pjz57xF4D9OJWR9oX2TCwSjxm5PBkykWtIgSH2VSotZ3RPpsn593R0zDQ5h_1dmJYfYnHgxp7h4jU7-JWxS04--2E4M8n3x5-FBMO5nk-IbCmF0BJ78xmgJBDR0QpxGc-i6ePF6A-E-RiwuhVnvP5fY92AtQ5o4lFrGS_gSVm9hNWzLpW-CfcT0kmFfcYGO4LQn5h196bw85wpsLgsHusKCShiS28-03jZl6djbTFrarLiZtbg9GJylE0v8OH2Dl05qFEGnZxadXIUmnKpxcFvo1jqqy0n_fgKvo2PLz-deN1fGzwtyKG9IqC-Y0ItNlGC2f90HEkygsDqIjRKx0FZltpS5DA6IPzjW0PWkio7lKnyh1q8hpWqrsptQIqAxkY6KpiWTpqiCHwRJYlvFCdHQzmAvV59-VVLzpH3mxqa8txN-QB2e8XmnX82OUWxoaRg5VMfHxavybM4XaKqsp67b0TKiWcxgK3WIBZSBC3rQ9q-DuDA6f3v4vPTLyP3sPPvn76H1Ww0zien51_fwHOCaLItOdyFlZvrefkWnjZm_s6Z-y9ZeQBJ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Latin+American+Clinical+Practice+Guidelines+on+the+Systemic+Treatment+of+Psoriasis+SOLAPSO+%E2%80%93+Sociedad+Latinoamericana+de+Psoriasis+%28Latin+American+Psoriasis+Society%29&rft.jtitle=International+journal+of+dermatology&rft.au=Kogan%2C+Nora&rft.au=Raimondo%2C+N%C3%A9lida&rft.au=Gusis%2C+Simon+E.&rft.au=Izcovich%2C+Ariel&rft.date=2019-08-01&rft.issn=0011-9059&rft.eissn=1365-4632&rft.volume=58&rft.spage=4&rft.epage=28&rft_id=info:doi/10.1111%2Fijd.14471&rft.externalDBID=10.1111%252Fijd.14471&rft.externalDocID=IJD14471 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0011-9059&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0011-9059&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0011-9059&client=summon |